특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacov

작성자
관리자
작성일
2024-02-01 22:07
조회
57

Jung SY, Kim MS, Li H, Lee KH, Koyanagi A, Solmi M, Kronbichler A, Dragioti E, Tizaoui K, CargninS, Terrazzino S, Hong SW, Ghayda RA, Kim NK, Chung SK, Jacob L, Salem JE, Yon DK, Lee SW, Kostev K, Kim AY, Jung JW, Choi JY, Shin JS, Park

SJ, Choi SW, Ban K, Moon SH, Go YY, Shin JI, Smith L. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacovigilance database. Clinical and Translational Science

2022;15:501–513.


Abstract



On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC-CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug-induced CV-ADRs from COVID-19 effects, we restricted analyses to patients with COVID-19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08–3.29), bradycardia (aOR: 2.09, 95% CI: 1.24–3.53), and hypotension (aOR: 1.67, 95% CI: 1.03–2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC-CMs in time- and dose-dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin.


 

논문확인(클릭시이동)
전체 52
번호 제목 작성자 작성일 추천 조회
52
[특허] 콘케이브와 진탕배양 기법으로 형성된 전분화능 줄기세포 유래 신경세포 제조방법 및 이에 의해 제조된 3D 신경 오가노이드를 통한 약물 독성 평가방법
관리자 | 2024.02.22 | 추천 0 | 조회 40
관리자 2024.02.22 0 40
51
[특허] 중간엽줄기세포 패치 공배양 기법을 이용한 투명 배상체 유래 간세포 제조방법 및 이에 의해 제조된 3D 간 오가노이드를 통한 약물 독성 평가방법
관리자 | 2024.02.22 | 추천 0 | 조회 39
관리자 2024.02.22 0 39
50
[특허] 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
관리자 | 2024.02.22 | 추천 0 | 조회 37
관리자 2024.02.22 0 37
49
[특허] 인공 신경망을 이용한 심장 부정맥 유발약물의 스크리닝 방법
관리자 | 2024.02.20 | 추천 0 | 조회 44
관리자 2024.02.20 0 44
48
[특허] 3 차원 세포 배양용 미세유체칩 및 이를 이용한 3 차원 세포 배양방법
관리자 | 2024.02.20 | 추천 0 | 조회 44
관리자 2024.02.20 0 44
47
Translation reinitiating in c.453delC frameshift mutation of KCNH2 producing functional hERG K+ channels with mild dominant neg
관리자 | 2024.02.02 | 추천 0 | 조회 48
관리자 2024.02.02 0 48
46
Extracellular matrix cues regulate the differentiation of pluripotent stem cell-derived endothelial cells.
관리자 | 2024.02.02 | 추천 0 | 조회 51
관리자 2024.02.02 0 51
45
Ultraefficient extracellular vesicle–guided direct reprogramming of fibroblasts into functional cardiomyocytes.
관리자 | 2024.02.02 | 추천 0 | 조회 52
관리자 2024.02.02 0 52
44
In vitro maturation of human pluripotent stem cell-derived cardiomyocyte: A promising approach for cell therapy.
관리자 | 2024.02.02 | 추천 0 | 조회 62
관리자 2024.02.02 0 62
43
Enhancement strategy for effective vascular regeneration following myocardial infarction through a dual stem cell approach.
관리자 | 2024.02.02 | 추천 0 | 조회 57
관리자 2024.02.02 0 57